Partner With Us NRI

Zydus Lifesciences Ltd share Price

Company details

6M Return 25.59%
1Y Return 41.24%
Mkt Cap.(Cr) 52,138.63
Volume 831,746
Div Yield 1.16%
OI Chg %
Volume 831,746

Open Free Trading Account Online with ICICIDIRECT

Decent performance; US pipeline, India traction key…

About The Stock

    Zydus is a leading pharma company with family pedigree having a presence in domestic branded formulations, US generics and is in the process of repurposing itself into niche areas of specialty pharmaceuticals, biosimilars and vaccines.
    • FY22 revenue break-up – US: 39%, India: 32%, Wellness: 13%, Europe & emerging markets including countries in LatAm, Asia Pacific & Africa: 10%
    • Zydus is the fourth largest pharma company in India with 14 brands among Top 300 pharma brands in India and nine with ₹ 100 crore+ sales


    India growth impacted by higher Covid base (9% YoY growth ex-Covid, generics portfolio and divested products) while US price erosion eased.
    • Sales were up 2% YoY to ₹ 4073 crore (ex-Covid: up 11% YoY)
    • EBITDA was at ₹ 833 crore, down 14% YoY with margins at 20.5%
    • Adjusted PAT was at ₹ 529 crore (down 11% YoY)

Click here for full recommendation

Research view on more stocks

Zydus Lifesciences Ltd.

Q4FY23 Quarterly & FY23 Annual Result Announced for Zydus Lifesciences Ltd.

Pharmaceuticals firm Zydus Lifesciences announced Q4FY23 & FY23 results:


  • Revenue from Operations at Rs 50,106 million, up 32% over last year.
  • Research & Development (R&D) investments for the quarter stood at Rs 3,541 million (7.1% of revenues).
  • EBITDA for the quarter was Rs 12,556 million, up 75% YoY. EBITDA margin for the quarter was 25.1% against 18.9% in Q4 FY22. Adjusted for one-time COVID related inventory provision of Rs 1,435 million made in Q4 FY22, EBITDA grew by 46% YoY.
  • Net Profit adjusted for the exceptional expense in Q4 FY23 was Rs 8,979 million, up 126% YoY. Excluding the exceptional expense, one-time COVID related inventory provision and profit/ (loss) of discontinued operations, net profit was up by 71% YoY.
  • Capex (organic) for the quarter was Rs 2,040 million.


  • Revenue from Operations at Rs 1,72,374 million, up 14% over last year.
  • Research & Development (R&D) investments for the year stood at Rs 12,363 million (7.2% of revenues).
  • Reported EBITDA for the year was Rs 38,599 million, up 16% YoY. EBITDA margin for the year was 22.4% against 22.1% last year. Adjusted for COVID related inventory provision made in FY23 and FY22, EBITDA margin for the year was 23.1% against 23.3% last year.
  • Net Profit adjusted for the exceptional items and profit/ (loss) of discontinued operations, was Rs 25,691 million, up 19% YoY.
  • Capex (organic) for the year was Rs 9,579 million.
  • Net Debt to Equity ratio as on 31st March, 2023 was -0.03x while Net Debt to EBITDA stood at -0.14x at the end of March, 2023. Net Cash (negative Net Debt) as on March 31, 2023 was Rs 5,461 million.

We are delighted to have maintained growth momentum across all our key businesses throughout the year, ending the fiscal year on a strong note with steady improvement in profitability and balance sheet health. We are well poised to maintain growth momentum, with India geography likely to hold double-digit growth, the US business continuing to leverage our robust product pipeline and agile supply chain and scale-up of our emerging market business. We are committed to upholding high quality management standards and working constantly to enhance them. We are advancing our innovation efforts with an aim to serve the patients’ needs across markets and improving their health outcomes. Dr. Sharvil Patel, Managing Director - Zydus Lifesciences Limited

Result PDF

View Other Company Results


Investment recommendation

Decent performance; US pipeline, India traction key…
Call Date
04 Feb 2023
Entry Price 430.00
Target Price 500.00
12-18 Month


Operating Profit
Profit after Tax
Reserves and Surplus
Operating Profit
Profit after Tax

Zydus Lifesciences Ltd Stocks COMPARISION


Equity Capital: 16,999.60 Cr FV: 1.00

Period MF Net Purchase / (sold) FII Net
LAST 1M 6,206.94 33,704.16
LAST 3M 18,301.56 58,999.00
LAST 6M 64,412.59 43,706.77
LAST 12M 118,019.00 92,784.99
Zydus Lifesciences receives USFDA approval for Tadalafil Tablets

Jun 07, 2023 l BSE Announcement

Zydus Lifesciences Limited - Copy of Newspaper Publication

Jun 06, 2023 l NSE Announcement

Date Action Type Ratio
Jul 28, 2023 Dividend 600
Jul 28, 2022 Dividend 250
Jul 28, 2021 Dividend 350

Zydus Lifesciences Ltd Information

Stock PE (TTM)
Promoter Holding
Book Value
Registered Address

Zydus Corporate Park S No 536, Khoraj Sarkhej-Gandhinagar H/W, Ahmedabad, Gujarat, 382481

Tel : 91-079-26868100
Email : upen.shah:zyduscadila.com
Website : http://www.zyduscadila.com

Sharepro Services India P Ltd

AGM Date (Month) : Aug
Face Value Equity Shares : 1
Market Lot Equity Shares : 1
BSE Code : 532321
Book Closure Date (Month) : Jul/Aug
BSE Group : A
ISIN : INE010B01027

FAQ’s on Zydus Lifesciences Ltd Shares

You can buy Zydus Lifesciences Ltd shares through a brokerage firm. ICICIdirect is a registered broker through which you can place orders to buy Zydus Lifesciences Ltd Share.

Company share prices and volatile and keep changing according to the market conditions. As of Jun 07, 2023 03:59 PM the closing price of Zydus Lifesciences Ltd was ₹ 515.10.

Market capitalization or market cap is determined by multiplying the current market price of a company’s shares with the total number of shares outstanding. As of Jun 07, 2023 03:59 PM, the market cap of Zydus Lifesciences Ltd stood at ₹ 52,138.63.

The latest PE ratio of Zydus Lifesciences Ltd as of Jun 07, 2023 03:59 PM is 21.65

The latest PB ratio of Zydus Lifesciences Ltd as of Jun 07, 2023 03:59 PM is 0.34

The 52-week high of Zydus Lifesciences Ltd is ₹ 530.85 while the 52-week low is ₹ 329.80

According to analyst recommendations, Zydus Lifesciences Ltd has a “Buy” rating for the long term.

Download Our App

market app
market app